15 October 2014

Receipt of $1.14 million R&D Tax Incentive payment

Antisense Therapeutics Limited ("ANP" or "the Company") would like to advise that the Company has received from the Australian Taxation Office an R&D Tax Incentive payment of $1.14 million in relation to R&D activities for the 30 June 2014 financial year.

As advised in the Company's recent capital raising announcement, ANP will no longer need to draw on the funding facility with Macquarie Bank Limited (as announced on the 2 June 2014). With the receipt of the R&D Tax Incentive payment this funding facility will now terminate. Accordingly approximately $1.09 million will be available to the Company net of costs.

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc. world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with multiple sclerosis, ATL1103 a second-generation antisense drug designed to block GHr production and thereby lower blood IGF-I levels and is in clinical development as a potential treatment for growth and other GH-IGF-I disorders, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.

Contact Information: Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (3) 9827 8999